Before this development, the medical community had largely overlooked Lp(a). Discovered back in 1963, it was relegated to the sidelines while LDL took center stage in cardiology discussions. The prevailing wisdom suggested that raising HDL would be beneficial — but that didn’t pan out. So now, with new data emerging, the conversation is shifting again.

What changed? Recent studies show that people with high levels of Lp(a) have more than double the risk of heart attacks compared to those without elevated levels. An estimated one in five people worldwide has elevated Lp(a). That’s a staggering number when you think about it. Yet, less than 1% of adults were tested for it in the U.S. in 2024. Why? Perhaps because the medical community hasn’t fully embraced the importance of this biomarker until now.

Pharmaceutical giants like Novartis, Amgen, and Eli Lilly are diving headfirst into this space. They’re not just dipping their toes; they’re in late-stage trials aimed at determining whether drugs that cut Lp(a) can effectively protect against heart attacks. Novartis’ drug pelacarsen aims to lower Lp(a) levels significantly — and results show these experimental drugs can slash levels by over 80%. That’s no small feat.

But it’s not just about numbers and percentages; there’s a human element here too. Dr. Steve Nissen points out the need for an open mind in cardiology — after all, past assumptions about HDL didn’t hold up under scrutiny. Jay Bradner emphasizes the clarity of genetic signals supporting this shift and sees it as a smart bet for pharmaceutical companies looking to innovate.

Still, uncertainties linger. What exact levels of Lp(a) need to be lowered to prevent heart attacks? No one has definitively answered that yet. Additionally, timelines for results from Novartis’ trial have been delayed due to slower-than-expected occurrences of heart attacks among participants — raising questions about how quickly we can expect breakthroughs.

This new focus on Lp(a) could reshape our understanding of cardiovascular disease and how we approach prevention and treatment. As we stand at this crossroads, one question looms large: will these efforts lead to effective therapies that change lives or will they be another missed opportunity in the complex world of cholesterol management?

Сообщение Cholesterol: Pharmaceutical Companies Bet on : The Rise of Lp(a) появились сначала на Latest News UK.